Related Experiment Video
Updated: Aug 21, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate
Arash Delavar1,2, Sally L Baxter3,2
1Department of Ophthalmology, University of California, La Jolla, California, USA.
Insights
Antiphospholipid syndrome patients on hydroxychloroquine may develop vision loss from retinal atrophy, not just retinopathy. This risk motivated a patient to resume anticoagulation therapy.
Area of Science:
- Ophthalmology
- Rheumatology
- Vascular Medicine
Background:
- Hydroxychloroquine (HCQ) is used for autoimmune conditions like antiphospholipid syndrome (APS).
- Long-term HCQ use can cause retinopathy, necessitating regular screening.
- Patients with APS are at risk for thrombotic events, often managed with anticoagulation.
Abstract:
A patient in her late 50s with antiphospholipid syndrome presented to general ophthalmology clinic for annual hydroxychloroquine retinopathy screening. She had taken 400 mg hydroxychloroquine daily for over a decade. She denied any visual changes and visual acuity was 20/20. Her examination and fundus photos were normal, but macular optical coherence tomography of the right eye demonstrated inner retinal atrophy and visual field tests revealed a corresponding paracentral scotoma, consistent with a prior cilioretinal artery occlusion. Prior testing from visits with other ophthalmologists revealed that this occlusion had occurred previously, but she had only been informed of not having hydroxychloroquine retinopathy. The possibility of vision loss prompted her to reconsider her prior decision to discontinue anticoagulation. This case demonstrates how anchoring bias may lead clinicians astray, and how the risk of blindness is a strong motivator for patients regarding anticoagulation.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Peripheral Artery Disease III: Interprofessional Care
Venous Thrombosis I: Introduction

